Adjuvance announce clinical results of its next-gen saponin adjuvant
First results demonstrate favourable tolerability of TQL-1055 at all dose levels
First results demonstrate favourable tolerability of TQL-1055 at all dose levels
The two-year donation supports the development of clinical tests for Covid-19 severity assessment and the focus on the development of simple immunoassays using single molecule counting technology
As part of the PMGDisha-CoWIN integration, Mercer | Mettl has aggregated the database of 5 crore Aadhaar-authenticated and registered candidates, which is now being utilized to deliver vaccinations to the last mile populace
Viraleze was developed for application in the nasal cavity to help reduce exposure to respiratory viruses, including SARS-CoV-2. The product is registered for sale in Europe and India, and available online in certain markets
CDSCO gives the green signal as HGCO19 was safe, tolerable and immunogenic in the participants of the study
When the Delfi technology was used as a pre-screen to determine if a low dose CT (LDCT), should be performed, the combined approach led to the detection of 90% of lung cancers, including 80% of stage I cancers
Researchers from IIT Bombay and QIMR Berghofer Medical Research Institute, Australia have developed this method, based on the Agilent Cary 630 FTIR Spectrometer
It aims to provide trained healthcare manpower, home care solutions, and end-to-end hospital management services enabling quick & on-demand deployment
In FY21, the company reported a net profit of Rs 419 crores compared to Rs 101 crores in FY 20 and consolidated total income at Rs 6092 crores, up 19% Y-o-Y
The group, known as the HIV Obstruction by Programmed Epigenetics (HOPE) Collaboratory, will be led by researchers at Gladstone Institutes, Scripps Research Florida, and Weill Cornell Medicine. Their approach, which aims to both silence and permanently remove HIV from the body, takes advantage of knowledge about how other viruses have become naturally inactivated over time.
Subscribe To Our Newsletter & Stay Updated